Data Alone Can’t Make Health Improvements Happen

Posted by Pratap Khedkar on Thu, Nov 14, 2019

The data changing hands in the new data-driven healthcare partnership between Google and St. Louis-based health system Ascension runs the gamut from patient names and birth dates to lab results and previous hospitalizations. The duo may have its sights set on using this information to personalize care and lower costs, but data privacy alarms are going off everywhere, raising questions about who really owns patient medical records and whether the benefits of sharing patient data outweigh the risks to the patient/consumer.


>
Read More

Why Metadata is Key to Improving Customer Experiences

Posted by Carrie Reininger on Wed, Nov 13, 2019

Jones Jaick co-wrote this blog post with Carrie Reininger. 

There’s a lot of buzz around the term metadata among marketers today, but what exactly is metadata, and why does it make so many people squirm?

Metadata simply means data about data. In the context of marketing and promotion, metadata is crucial because it helps marketers and campaign managers track a plethora of promotional data and organize it to draw insights about content, channel and tactic performance. In a world where marketers are chasing customer centricity (targeting the right customer, with the right message, through the right channel, at the right time), capturing marketing activity and engagement data is critical. By taking control of metadata, marketers can optimize their campaigns through data-driven, accurate and actionable insights and get faster response and turnaround times. Here are the benefits of tagging and leveraging metadata and accurately tagging assets:


>
Read More

All in All, It’s Just Another Crack in the Rebate Wall

Posted by Joe Stevens on Mon, Nov 11, 2019

Howard Deutsch co-wrote this blog post with Joe Stevens.

As the end of 2019 nears, a critical drug pricing question remains unanswered: Is the pharma “rebate wall” crumbling or are the rumors of its demise exaggerated? With the current “high list price, high rebate” model, pharma has been operating in a worst of both worlds scenario, taking blame for high list prices without reaping profits commensurate with those prices. Looking to break this cycle, pharma companies are beginning to bypass government and regulatory bodies, health insurers and PBMs in their efforts to address the rebate issue themselves, and we think that’s a wise move.


>
Read More

How Emerging Pharma Companies Can Succeed in the European Market

Posted by Ben Hohn on Wed, Nov 06, 2019

Judith Kulich, Cody Powers, Amer Dzankic, Mark Rayward-Smith and Renuka Agarwal co-wrote this blog post with Ben Hohn.

The emerging pharma landscape continues to grow in Europe. ZS research shows that around 900 companies are focused on novel therapeutic development, and more than 50% of these companies are concentrated in the U.K., France, Germany and Switzerland, with oncology representing the greatest number of assets (around 30%) as a therapeutic area.


>
Read More

Worried About Automation? 'Human-in-the-Loop' Protocols Offer Comfort and New Opportunities

Posted by Mike Jakymiw on Thu, Oct 31, 2019

Satish Jha co-wrote this post with Mike Jakymiw

Keeping someone “in the loop” means keeping them informed or involved. The term human-in-the-loop (HITL) means involving humans in processes that leverage innovations like AI, robotics and machine-learning algorithms. HITL ensures that a process isn’t run automatically without human supervision. On the surface, this might seem like distrust of automation and AI, but it’s a layer of precaution used to avoid mistakes or misses that AI and robots can easily make. More importantly, HITL will enhance these processes.


>
Read More